- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Senate passes Drug Quality and Security Act
- Diplomat becomes distributor of recently approved cancer drug
- Lipitor may be the first statin to switch to OTC
NEW YORK — A Food and Drug Administration expert panel has given a favorable vote to a drug made by Pfizer for tumors, Pfizer said Tuesday.
The FDA’s Oncologic Drugs Advisory Committee voted 8-2 that Sutent’s (sunitinib malate) benefits outweigh its risks in the treatment of unresectable pancreatic neuroendocrine tumors.
While the FDA is not bound by advisory committee votes, it takes them into consideration when deciding whether or not to approve a drug.